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For progressive interstitial pneumonia (progressive IP) that accompanies diﬀuse systemic sclerosis (diﬀuse SSc), no treatment
guidelines have yet been established, and it is a complication with a poor prognosis. We herein report a case in which combination
therapy of a low-dose corticosteroid and low-dose azathioprine was performed for progressive SSc-IP in a 64-year-old female
whose respiratory function was severely damaged for a long period of time and for whom improvement was achieved. The
beneﬁcial eﬀect has continued for 3 years with no side eﬀects being observed during the course.
1.Introduction
Systemic scleroderma (SSc) is a systemic autoimmune disor-
der of the gastrointestinal tract, lungs, and kidneys, and so
forth, which has dermal sclerosis as a major characteristic.
SSc has IP as a complication at a frequency of 44 to 75% [1,
2]. SSc-IP normally progresses slowly, but in diﬀuse SSc-IP,
there are cases in which progression is rapid and also cases in
which the respiratory function is damaged for a long period
of time [3]. No treatment guideline has been established
for progressive SSc-IP. Treatment methods that have been
attempted most frequently are oral cyclophosphamide (CY)
andintravenouspulseCY(IVCY).Althoughimprovementin
respiratory function has been obtained by these methods for
a short period of time of 1 to 2 years, they are not easy to be
applied for longer periods of time due to serious side eﬀects
[4, 5].
Azathioprine (AZA) inhibits purine nucleotide synthesis
a n de x e r t sa ni m m u n o s u p p r e s s i v ee ﬀect. A report exists
in which respiratory function stabilized upon switching
treatments to AZA as a maintenance therapy after IVCY was
performed monthly for 6 months for SSc-IP in addition to
a low-dose corticosteroid [6]. Moreover, a report exists in
which combination therapy of a steroid and AZP improved
the survival rate of idiopathic interstitial pneumonia [7].
BecauseAZA has fewerserious side-eﬀectsthanCY,thereis a
possibilitythatitcanalsobeusedforSSc-IPforalongperiod
of time.
In this paper, we describe a case in which continuous
improvement of IP was observed with combination therapy
of a low-dose corticosteroid and AZA for a case of SSc-IP in
whichthepulmonarydamagehadinveteratelyprogressedfor
al o n gp e r i o do f1 2y e a r s .
2.CaseReport
A 52-year-old female was admitted to our hospital for dry
cough and exertional dyspnea (Hugh-Jones classiﬁcation
(H-J) class II) on July 1994. High-resolution computed
tomography (HRCT) of the chest showed a reticular shadow
on the dorsal side of both lower lungs, ground-glass opacity
(GGO), and traction bronchiectasis (TBE), and she was
diagnosed as having IP. Around January 2000, Raynaud’s
phenomenon and, in the distal portion of the limbs,
dermal sclerosis appeared. The dermal sclerosis diﬀusely
progressed throughout the entire body thereafter, and she
was consequently diagnosed as having IP followed by
SSc. The clinical course thereafter is shown in Figure 1
and the chest HRCT ﬁndings in July 2003 are shown in2 Case Reports in Rheumatology
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Figure 1: Clinical course. TLC: total lung capacity, VC: vital capacity, FVC: forced vital capacity, FEV1/FVC: forced expiratory volume in
1s/forced vital capacity, DLCo: carbon monoxide diﬀusing capacity, and NT: not tested.
(a) July, 2003 (b) April, 2006 (c) September, 2008
Figure 2: Course of chest HRCT. (a) Consolidations, ground-glass opacities (GGO), and traction bronchiectasis (TBE) were noted on chest
HRCT at July, 2003. (b) Consolidations, GGO, and TBE increased on admission in April, 2006, compared with that in April, 2003. (c)
Consolidations, GGO, and TBE improved with 10mg/day of prednisolone and 75mg/day of azathioprine at September, 2008.
Figure 2(a). In July 2003, the SpO2 was 96% (room air),
the KL-6 was 554U/mL. In a respiratory function test, the
TLC% was found to be 46.5% and the FVC% was 55.1%.
From October 2005, exertional dyspnea had exacerbated
from H-J class II to IV, the SpO2 decreased to 87% (room
air), and she was admitted to our hospital on April 3,
2006. On physical examination, ﬁne crackles were observed
in both lower lungs, and dermal sclerosis was diﬀusely
observed in the facial surface and all limbs. In the laboratory
ﬁndings, the WBC was 7240/µL (neutrocyte 69.2%) andCase Reports in Rheumatology 3
the CRP was 3.20mg/dL. The KL-6 was 955U/mL. The
antinuclear antibody was positive (speckled pattern), but the
other various disease-speciﬁc autoantibodies were negative
including anti-Scl-70 antibody. In a respiratory function test,
the TLC% decreased to 36.0% and the FVC% to 45.1%.
In the chest X-ray, both lower lungs shrank, the reticular
shadow increased, and the chest HRCT showed increase in
the area of the consolidation, GGO, and TBE (Figure 2(b)).
SSc-IP was determined to have exacerbated, and on April
11, 2006, combination therapy of 10mg/day of prednisolone
(PSL) and 75mg/day of AZA was initiated. The IP gradually
improved, and in September 2008, the dyspnea improved
to H-J class I and the SpO2 increased to 97%. The KL-
6 decreased to 572 U/mL, and in a respiratory function
test, the FVC% showed improvement to 57.3%. Upon chest
HRCT, decrease of the GGO, consolidation, and TBE were
observed (Figure 2(c)). During the course, no obvious side
eﬀects due to the concomitant therapy of PSL and AZA were
observed.
3. Discussion
For progressive SSc-IP, the treatment methods most often
used are oral CY and IVCY, and it has been reported
that respiratory function improves or stabilizes during a
f o l l o w - u pp e r i o do f1t o2y e a r s[ 4]. However, upon long-
term followup, the presence of relapse cases after treatment,
an unimproved survival rate, and serious side eﬀects such
as hematuria, infertility, bone marrow suppression, malig-
nancy, and infection are problems, in addition to CY not
being easy to use for SSc-IP for a long period of time [5].
AZA inhibits purine nucleotide synthesis and exerts an
immunosuppressive eﬀect mainly centering on T cells. A
report exists indicating the involvement of CD8+ T cells with
formation of the clinical state of SSc-IP [8] and there is a
possibility that AZA is eﬀective for SSc-IP.
Inthecasereportedherein,progressiveSSc-IPoveralong
period of approximately 12 years improved with combin-
ation therapy of low-dose PSL and AZA. During the follow-
up period of 30 months after the combination therapy,
there was no serious side eﬀects, thus resulting in suﬃcient
tolerability. Hoyles et al. reported that AZA was eﬀective as a
maintenance therapy for SSc-IP after combination therapy
of steroids and IVCY [6]. Dheda et al. have performed
combination therapy of low-dose steroids and AZA for 11
cases of SSc-IP and reported that the eﬀects of “improved”
(FVC% improved by 10% or more than the base line) in 5
patients and “stable” (FVC% improved by 10% or less) in
3 patients were obtained [9]. When the 8 cases of Dheda
et al. and the present case are compared, the 8 cases of
Dheda et al. showed a mean duration for IP of 18.45 ± 4.52
months and a mean FVC% of 54.25 ± 3.53%, whereas the
present case showed a duration for IP of 171 months and
a FVC% of 45.1%, and is a case in which the respiratory
function was damaged for a much longer period of time. As
in our case, there is a possibility that even SSc-IP in which
the respiratory function was severely damaged for a long
period of time may improve with combination therapy of
a low-dose steroid and AZA, and it is believed to be worth
attempting.
In the presentcase,no obvious side eﬀectsduetosteroids
and AZA were observed. AZA has fewer serious side eﬀects
than CPA and there is a possibility that it can be used for
a long period of time. However, AZA may also possibly
cause side eﬀects such as digestive symptoms, bone marrow
suppression, hepatic damage, and increased susceptibility to
infection although less severe than those of CY. Dheda et al.
havealsoreportedthatamongthe11casesofSSc-IPinwhich
A Z Aw a su s e d ,s i d ee ﬀects of nausea in 1 case and decreased
WBC in 1 case were observed, and, therefore, it is necessary
to pay attention to the expression of side eﬀects in using AZA
for SSc-IP.
Asinthepresentcase,combinationtherapyofalow-dose
steroid and AZA is also eﬀective for cases of SSc-IP in which
therespiratoryfunctionhasbeenseverelydamagedforalong
periodoftime,indicatingthatitwasatreatmentmethodthat
could be used for a long period of time. However, because
there are still only a few cases in which AZA is used for SSc-
IP, it is necessary to evaluate the eﬃcacy and safety after the
future accumulation of more cases.
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